REVENIO

Correction: Revenio Group Corporation to transfer shares related to the share-based awards to CEO

Revenio Group Corporation, Stock Exchange Release, February 11, 2022 at 4.45 p.m. (EET)

Correction: Revenio Group Corporation to transfer shares related to the share-based awards to CEO

Yesterday, on 10 February 2022 at 10:20 a.m. (EET), Revenio Group Corporation published a stock exchange release on transferring shares related to the share-based awards to CEO. In the release, the number of treasury shares hold by the company were incorrectly stated. The correct phrasing would have been: After the transfer, the company holds 104,376 treasury shares.

Below the corrected release as a whole:

The Board of Directors of Revenio Group Corporation decided, on 10 February 2022, on the basis of the share issue authorisation granted to the Board of Directors by the company's Annual General Meeting held on 17 March 2021, to issue shares, altogether 400 Revenio Group Corporation shares held by the company, in a directed free share issue to CEO Jouni Toijala for the payment of share-based award under the 2021-2023 LTI RS-program from year 2021.

The shares to be issued in the free directed share issue will be issued in accordance with the terms of the company's current share-based incentive plan, which will improve CEO`s permanence and work motivation, so there is a particularly weighty financial reason under the Companies Act (9:4.1). The key terms of the share-based incentive plan are described in the company's 2020 Remuneration Report.

After the transfer, the company holds 104,376 treasury shares.

Revenio Group Corporation
Board of Directors

For further information, please contact:
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. In addition, the Group's eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring and data analytics capabilities.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Correction: Revenio Group Corporation to transfer shares related to the share-based awards to CEO